Archive for August, 2008:

GSK’s “scary” HIV ads are ok with me

Saturday 30 August 2008

The Wall Street Journal (Glaxo’s HIV-Drug Ads Draw Critics) and Wall Street Journal Health Blog (Are Ads for HIV Drugs Too Scary?) wrote earlier this week about consumer-directed advertising for HIV drugs from GlaxoSmithKline (GSK) and Bristol-Myers Squibb (BMS). A GSK ad shows a picture of shark-infested waters and tells patients, “Don’t take a chance –stick with the HIV medicine that’s working for you.” Another GSK ad asks, “Will the HIV medicine make my skin or eyes turn yellow?” In my favorite, a BMS ad shows a toilet with a huge stack of magazines on the back of it. “Living with HIV doesn’t mean you have to live here,” it says, and urges patients to check with their doctors to see if they can take something that is less likely to cause disarrhea.
Some patient advocates and researchers complain that the ads are too frightening or will interfere with the doctor/patient relationship by making patients less receptive to their physicians’ advice to switch medications. I know the experts quoted in the story and am sympathetic to their points. They want patients to receive the most appropriate, evidence-based treatment, and not have care influenced by commercial interests.

(Continue reading…)

More About Ephedra Diet Pills

Friday 29 August 2008

Previously I talked about various general aspects of Ephedra and its relation with weight loss. Here is further information to complete the topic.

(Continue reading…)

Cavalcade of Risk is up at Healthcare Manusmission

Friday 29 August 2008

Check out the latest Cavalcade of Risk blog carnival, hosted this time by Healthcare Manumission.

(Continue reading…)

Two views on the Avastin/Lucentis debate

Friday 29 August 2008

Regular readers remember last year’s Avastin/Lucentis debate here on the Health Business Blog. To recap: the drugs are essentially the same and they’re made by the same company. Avastin is a cancer drug and Lucentis is used in the eye. Compounding pharmacists found a way to repackage Avastin into the much smaller dosages for ophthalmic use, thus making an ~$60-80 Avastin equivalent to a ~$2000 Lucentis dose. The manufacturer, Genentech, found itself caught in the middle.

(Continue reading…)

Are prescription drugs going the way of Napster, YouTube and iTunes?

Thursday 28 August 2008

The distribution of prescription pharmaceuticals is beginning to take on some of the characteristics of online videos and music. Traditionally, access to prescriptions works as follows:

(Continue reading…)